1. Hruska K.A., Methew S., Lund R. et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74 (20): 148-157.
2. Moe S., Chen N. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216.
3. Stevens L.A., Li S, Wang C. et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010; 55 (3 Suppl 2): S23-S33.
4. Meng J., Wassel C.L., Kestenbaum B.R. et al. Osteoporotic Fractures in Men (MrOS) Study Group. Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study. Am J Epidemiol 2010; 171 (8): 909-916.
5. Amann K., Gross M.L., London G.M., Ritz E. Hyperphosphatemia: a silent killer in patients with renal failure. Nephrol Dial Transplant 1999; 14: 2085-2087.
6. Guerin A.P., London G.M., Marchais S.J., Metivier F. Arterial stiffness and vacular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-102.
7. Kramer H., Toto R., Peshock R. et al. Association between chronic kidney disease and coronary artery calcification. The Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513.
8. Shioi A., Nishizawa Y. Vascular calcification in chronic kidney disease: pathogenesis and clinical implications. J Ren Nutr 2009; 19 (1): 78-81.
9. Mehrotra A., Budoff M., Christenson P. et al. Determinants of coronary artery calcification in diabetics with andwithout nephropathy. Kidney Int 2004; 66: 2022-2031
10. National Kidney Foundation (NKF). K/DOQI clinical practice guidelines for bone metabolism and disease in chroniсkidney disease. Am J Kidney Dis 2003; 42: S1-S201.
11. Suki W.N., Zabaneh R., Cangiano J.L. et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
12. St Peter W.L., Liu J., Weinhandl E., Fan Q. A comparison of sevelamer and calcium-based phosphate-binders on mortality, hospitalizations and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51: 445-454.
13. Block G.A., Raggi P., Bellasi A. et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
14. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
15. Borzecki A.M., Lee A., Wang S.W. et al. Survival in end-stage renal disease: calcium carbonate vs sevelamer. J Clin Pharmacy Ther 2007; 32: 617-624.
16. Yilmaz M.I., Sonmez A., Saglam M. et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012; 59 (2): 177-185.
17. Tonelli M., Wiebe N., Culleton B. et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866.
18. Chertow G.M., Burke S.K., Raggi P. et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
19. Chertow G.M., Dillon M., Burke S.K. et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium - Strategies for the control of hyperphosphatemia and hyperparathyreoidism in hemodyalisis patients. Clin Nephrol 1999; 51: 18-26.
20. Qunibi W., Moustafa M., Muenz L.R. et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. Am J Kidney Dis 2008; 51: 952-965.
21. Grima D.T., Dunn E.S., Bernard L.M., Mendelssohn D.C. Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis. Curr Med Res Opin 2013; 29 (2): 109-115.
22. Bernard L., Mendelssohn D., Dunn E. et al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ 2013; 16 (1): 1-3.
23. Ferramosca E., Brucke S., Chasan-Taber S. et al. Potential antiatherogenic and anti-inflammatory prorepties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825.
24. Ketteler M., Rix M., Fan S. et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3: 1125-1130.
25. Sun P.P., Perianayagam M.C., Jaber B.L. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. J Ren Nutr 2009; 19 (5): 432-438.
26. Kubotera N., Prokopienko A.J., Garba A.O., Pai A.B. Endotoxin binding by sevelamer: potential impact on nutritional status. Int J Nephrol 2013; 13: 954-956.
27. Navarro-González J.F., Mora-Fernández C., Muros de Fuentes M. et al. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011; 6(9): 2272-2279.
28. Raj D.S., Carrero J.J., Shah V.O. et al. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis 2009; 54 (6): 1072-1080.
29. Yap Y.S., Chuang H.Y., Chi W.C. et al. Factors related to nephrotic-range proteinuria in late-stage chronic kidney disease patients with diabetes mellitus. Int Urol Nephrol 2013 Jan 26. [Epub ahead of print]
30. Yap Y.S., Chi W.C., Lin C.H. et al. Hyperphosphatemia is associated with overt proteinuria in non-diabetic patients with late-stage chronic kidney disease: a cross-sectional study. Int Urol Nephrol 2013; 45 (1): 163-172.
31. Vlassara H., Cai W., Chen X. et al. Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift. J Gerontol A Biol Sci Med Sci 2012; 67 (12): 1410-1416.
32. Vlassara H., Uribarri J., Cai W. et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 2012; 7(6): 934-942.
33. Draca N., Lazic R., Simic P. et al. Potential beneficial role of sevelamer hydrochloride in diabetic retinopathy. Med Hypotheses 2013 Jan 25. [Epub ahead of print]
34. Милованова Л.Ю., Милованов Ю.С., Добросмыслов И.А., Моисеев С.В. Севеламера гидрохлорид - новые перспективы в лечении и коррекции гиперфосфатемии у больных хронической болезнью почек III-V стадии. Клин нефрол 2012; 5-6: 49-53.

________________________________________________

V.V. FOMIN, E.M. SHILOV, A.A. SVISTUNOV, YU.S. MILOVANOV

I.M. Sechenov First Moscow Medical University, Ministry of Health of Russia